Clinical research on Placenta Polypeptides Injection combined with chemotherapy in treating advanced ovarian cancer
10.3969/j.issn.1671-8348.2017.07.021
- VernacularTitle:胎盘多肽注射液联合化疗治疗晚期卵巢癌的临床研究
- Author:
Wenjing HE
;
Xiaoyue FU
;
Lan XIE
- Keywords:
ovarian neoplasms;
placenta polypeptides;
paclitaxel;
paraplatin
- From:
Chongqing Medicine
2017;46(7):931-933
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of the Placenta Polypeptides injection combined with paclitaxel plus paraplatin(TC)chemotherapy in the treatment of advanced ovarian cancer.Methods Eighty patients with advanced ovarian cancer receiving tumor cytoreductive surgery were divided into the treatment group and control group,40 cases in each group.The control group accepted single TC chemotherapy,while on this basis the treatment group was added with the Placenta Polypeptides injection.The short-term effect,KPS scores and occurrence of chemotherapeutic toxic reactions were observed in both groups.Results The short-term effective rates in the treatment group and control group were 90.00％ and 87.50 ％ respectively,the difference was not statistically significant (P＞0.05);the living quality KPS score in the treatment group was significantly better than that in the control group,the difference indicated statistical significance(P＜0.05).The occurrence rates of adverse reactions,including leukopenia,nausea and vomiting,liver function damage,heart toxicity,muscle and joint pain were significantly lower than those in the control group (P＜0.05).Conclusion The Placenta Polypeptides injection combined with TC chemotherapeutic regimen in the treatment of advanced ovarian cancer could improve the quality of life of the patients,reduce the toxic and adverse reactions of chemotherapeutic drugs.
